Filter By Category
Archives
Share on -
AMENAMEVIR
Generic Name: AMENAMEVIR
ABSTRACT -
Amenamevir (ASP2151) is an anti-herpesvirus helicase-primase inhibitor. It inhibits the viral helicase-primase complex required for herpesvirus DNA replication and has activity against varicella-zoster virus and herpes simplex viruses. It is approved in Japan for herpes zoster, while availability and exact indications vary by country.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- Follow the approved local prescribing information where amenamevir is marketed.
- No universal worldwide dosing statement should be applied across countries.
- Treatment timing is important in herpesvirus infections; start only as directed by a clinician.
SIDE EFFECTS–
Possible side effects and safety concerns include:
- Headache
- Nausea, diarrhoea, abdominal discomfort, or reduced appetite
- Dizziness or malaise
- Rash or pruritus
- Liver enzyme abnormalities
- Hypersensitivity reactions
ALLRGIC REACTIONS–
Hypersensitivity to Amenamevir or related compounds/products may occur. Symptoms may include:
- Rash
- Urticaria
- Facial or throat swelling
- Wheezing
- Anaphylaxis
Important: Patients who develop an allergic reaction to Amenamevir should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS–
Amenamevir may interact with certain medicines, vaccines, protocols, or clinical conditions. Caution is needed with:
- CYP3A4 inducers may reduce exposure and antiviral effect.
- CYP3A4 inhibitors may increase exposure; follow local labeling.
- Medicines with overlapping liver-toxicity risk may require monitoring.
- Do not combine with other antivirals unless directed by a clinician.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Check local indication, dose, contraindications, and interaction guidance before prescribing.
- Use caution in hepatic impairment and in patients taking multiple interacting medicines.
- Do not delay urgent evaluation for ophthalmic zoster, neurological complications, or disseminated infection.
- Pregnancy and lactation require specialist advice.
WARNINGS –
- Use only under medical supervision and according to local labeling.
- Delayed treatment may reduce antiviral benefit in herpes zoster.
- Do not use in patients with known serious hypersensitivity to amenamevir.
- Keep out of reach of children.
Share on -
. Developed by